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Background: Patients with severe chronic obstructive pulmonary disease (COPD) are at increased risk of infection
by P. aeruginosa. The specific role of bronchiectasis in both infection and chronic colonization by this
microorganism in COPD, however, remains ill defined.
To evaluate the prevalence and risk factors for P. aeruginosa recovery from sputum in outpatients with severe
COPD, characterizing P. aeruginosa isolates by pulsed-field gel electrophoresis (PFGE) and focusing on the influence
of bronchiectasis on chronic colonization in these patients.
Methods: A case-cohort study of 118 patients with severe COPD attended at a Respiratory Day Unit for an acute
infectious exacerbation and followed up over one year. High-resolution CT scans were performed during stability
for bronchiectasis assessment and sputum cultures were obtained during exacerbation and stability in all patients.
P. aeruginosa isolates were genotyped by PFGE. Determinants of the recovery of P. aeruginosa in sputum and
chronic colonization by this microorganism were assessed by multivariate analysis.
Results: P. aeruginosa was isolated from 41 of the 118 patients studied (34.7%). Five of these 41 patients (12.2%)
with P. aeruginosa recovery fulfilled criteria for chronic colonization. In the multivariate analysis, the extent of
bronchiectasis (OR 9.8, 95% CI: 1.7 to 54.8) and the number of antibiotic courses (OR 1.7, 95% CI: 1.1 to 2.5) were
independently associated with an increased risk of P. aeruginosa isolation. Chronic colonization was unrelated to
the presence of bronchiectasis (p = 0.75). In patients with chronic colonization the isolates of P. aeruginosa retrieved
corresponded to the same clones during the follow-up, and most of the multidrug resistant isolates (19/21) were
harbored by these patients.
Conclusions: The main risk factors for P. aeruginosa isolation in severe COPD were the extent of bronchiectasis and
exposure to antibiotics. Over 10% of these patients fulfilled criteria for chronic colonization by P. aeruginosa and
showed clonal persistence, independently of the presence of bronchiectasis.
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Infectious exacerbations are the most important cause
of hospital admission and mortality in severe chronic
obstructive pulmonary disease (COPD) [1,2]. Potentially
pathogenic microorganisms (PPMs) such as Haemophilus
influenzae, Streptococcus pneumoniae, Moraxella catarrha-
lis and viruses are the leading causative agents of these
acute episodes, but P. aeruginosa accounts for 5-10% of
COPD exacerbations in these patients and has been associ-
ated with increased mortality [3].
It is widely accepted that the probability of bacterial
infection is higher in exacerbations appearing in severe
COPD patients. Two studies [4,5] have shown that indi-
viduals with a FEV1 below 50% of the reference level
have a six-fold higher risk of suffering exacerbations due
to H. influenzae and P. aeruginosa than patients with
mild or moderate COPD. Likewise, P. aeruginosa infec-
tion in COPD has also been related to risk factors such
as previous hospital admissions and use of oral cortico-
steroids or antibiotics [6-9] but the importance of these
individual determinants has not been elucidated. More-
over, the role of other potential factors such as bronchiec-
tasis, as a risk factor of P. aeruginosa in cursive infection-a
factor associated with severe airflow obstruction in COPD
[10], has been addressed only marginally [8]. In the con-
text of COPD exacerbation, the majority of guidelines
recommend specific treatment against P. aeruginosa in
patients reporting hospital admissions and/or recurrent
use of antibiotics or corticosteroids [11,12]; but the man-
agement of patients with repeated isolates of this PPM is
not well established. Recent studies based on pulsed-field
gel electrophoresis (PFGE) and polymerase chain reaction
have shown that most clones are cleared over time and that
only a minority persist [13]. In some patients a pattern of
chronic colonization by P. aeruginosa has been reported,
closely resembling those seen in cystic fibrosis [14,15]. Un-
fortunately, the relationship between chronic colonization
by P. aeruginosa, the pattern of clonal carriage and bronchi-
ectasis has not been evaluated to date.
The objectives of our study were to evaluate the preva-
lence and risk factors for, P. aeruginosa isolation in sputum
samples from outpatients with severe COPD, characterizing
P. aeruginosa isolates in these patients with pulsed-field
gel electrophoresis (PFGE) and focusing on the influence
of bronchiectasis and other risk factors, on bronchial
colonization in these patients.
Methods
Study subjects
Studied patients were part of a cohort of severe COPD
outpatients attending regularly Respiratory Diseases Day
Care Unit of Sabadell University hospital for scheduled
and exacerbation visits. This cohort included COPD
patients with a postbronchodilatador FEV1 below 50%from the reference who reported three or more severe
exacerbations in the previous year. Patients in the cohort
received education on self-care of the disease and a per-
sonal action plan, which included unscheduled visits to
the Unit when exacerbation symptoms appear.
Patients with severe COPD attending the Unit for an
exacerbation of COPD (ECOPD), defined by the pres-
ence of two or three of Anthonisen’s criteria [16], were
enrolled in this case-cohort study between January 2005
and March 2008, and followed from that episode on-
wards for a minimum period of one year.
Exclusion criteria: patients previously diagnosed with
bronchiectasis in view of symptoms and chest X-rays, pa-
tients <40 years of age, patients diagnosed with asthma,
cystic fibrosis or active neoplasia, those receiving chronic
treatment with oral corticosteroids or immunosuppressive
drugs for any reason and those patients under long-term
systemic or inhaled antibiotic therapy.
For the purpose of the study, patients were divided
into two groups according to the presence of P. aeruginosa
in sputum samples. Patients with one or more isolates
of P. aeruginosa from sputum at baseline or during the
follow-up, or with P. aeruginosa recoveries from spu-
tum samples in the previous year were assigned to the
P. aeruginosa group (PA group), and patients with no
previous recovery of P. aeruginosa and who did not present
this microorganism from their sputum samples during the
follow-up were assigned to the non-P. aeruginosa group
(non-PA group). Written informed consent was obtained
from each subject and ethical permission for the study
was obtained from the Sabadell University Hospital Ethics
Committee.
COPD clinical evaluation
COPD was defined as a postbronchodilator ratio of FEV1
to FVC of less than 0.7 according to the Global Initiative
for Chronic Obstructive Lung Disease (GOLD) criteria in
a patient with a smoking habit of more than 10 pack-years
[12]. At baseline, smoking history, severity of the disease,
BODE index [17], comorbidities (Charlson index) [18], use
of long-term home oxygen therapy, short-term treatments
with antibiotics and corticosteroids and hospitalizations due
to respiratory causes in the previous year were recorded.
All patients underwent the same scheduled clinical con-
trols at the Respiratory Day Care Unit [19] by the same
team of pulmonologists and received regular treatment
with long-term beta-agonists (LABA), anticholinergics and
inhaled corticosteroids (ICS). After the enrolment visit,
scheduled visits were recorded together with unscheduled
acute ECOPD visits, hospitalizations and mortality due to
respiratory causes. When acute symptoms appeared, chest
radiography was performed to rule out acute pneumonia
and decisions regarding antibiotic treatment and admission
were left to the discretion of attending physicians in
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the antibiotic prescriptions to the antibiogram. In case
of Pseudomonas aeruginosa isolation, oral quinolone
(ciprofloxacin or levofloxacin) or anti-pseudomonal intra-
venous therapy was initiated according to the severity of
the episode.
Isolation of P. aeruginosa in three or more consecutive
sputum cultures, taken at least one month apart during
a 6-month period, was considered as chronic colonization
by this PPM, independently of their recovery from exacer-
bation or stability periods and assuming the persistence of
the microorganism in the periods of stability between
exacerbations, [20]. In these patients, chronic treatment
with inhaled colistin plus long-term azithromycin was
indicated and prescribed from the diagnosis.
Bronchiectasis assessment
CT scans were performed in stability to evaluate bron-
chiectasis using a Multidetector CT scanner (Sensation
16 Siemens; Erlangen, Germany). High resolution CT
(HRCT) images were obtained, during fully suspended
inspiration in the supine position from the lung apex to
the diaphragm, using a thin-section technique (1-mm
collimation at 10-mm intervals) with the following pa-
rameters: 120 kVp tube voltage, 250 mA, and 1-second
scanning time. The images were obtained without injection
of contrast material and viewed in a lung window (window
width, 1500 HU; window level, −600 HU), using a high
spatial frequency algorithm for image reconstruction.
The CT scans were interpreted for the presence of bron-
chiectasis by two radiologists experienced (EC and XG) in
the interpretation of HRCT and blinded to the patient
grouping. Any differences in the reading were resolved by
consensus. Presence of bronchiectasis was based on the fol-
lowing criteria: non-tapering bronchus with internal diam-
eter 110% or greater than the adjacent pulmonary artery, or
visible bronchi within 1 cm of the costal or mediastinal
pleural surface [21]. Bronchiectasis extent was scored for
each pulmonary lobe, grading the lingula as a separate lobe.
Small bronchiectasis only visible in a single pulmonary seg-
ment were not considered, as they may appear in a signifi-
cant percentage of healthy population [22]. The grading
system proposed by Smith and coworkers [23] was used in
the study, scoring the absence of bronchiectasis as 0, bron-
chiectasis in fewer than 25% of bronchi as 1, in 25-49% of
bronchi as 2, in 50-74% as 3, and in 75% or more as 4.
Total score ranged from a minimum value of 0 points cor-
responding to absence of bronchiectasis, to a maximum
value of 24 points indicating involvement of all pulmonary
lobes. Patients with a score ≤ 1 were considered as normal.
Sputum bacteriology
Spontaneous sputum samples were collected in each
ECOPD before antibiotic administration. Stability sampleswere collected in scheduled visits at least one month after
the clinical resolution of any previous acute episode in pa-
tients producing spontaneous sputum. Recovered sputum
was processed within 60 minutes of collection in all cases,
and Murray-Washington criteria were used for the identi-
fication and selection of samples representative of bron-
chial secretions [24]. Sputum samples graded Murray
IV-V were cultured for PPMs in selective media accord-
ing to standard methods [25], and cultures were consid-
ered positive when PPMs were recovered.
Briefly, samples were vortexed for 30–60 seconds after
homogenization with sputolysin and 10 uL were cultured
using a calibrated loop in blood agar, blood agar with
nalidixic acid, chocolate agar and McConkey agar plates.
All plates were incubated in a 5% carbon dioxide incuba-
tor at 35°C and read at 18 and 48 hours. Gram-negative
and Gram-positive bacteria recognized as agents causing
respiratory infections, such as H. influenzae, Haemophi-
lus parainfluenzae, S.pneumoniae, M. catarrhalis, P. aer-
uginosa, Staphylococcus aureus, and Enterobacteriaceae
were considered as PPMs [26]. The presence or absence
of a mucoid phenotype was recorded for each isolate.
Antimicrobial susceptibility testing of P. aeruginosa isolates
were performed using the microdilution assay to determine
the minimum inhibitory concentration according to the
procedures of the Clinical and Laboratory Standards
Institute [27]. Multidrug resistance (MDR) in P. aeruginosa
was defined as resistance to three or more antibiotic groups
usually active against the PPM, including beta-lactams
(penicillins and cephalosporins), carbapenems, quinolones
or aminoglycosides, monobactam and polymyxins [28].
P. aeruginosa genotyping
P. aeruginosa isolates were frozen at -80°C and subse-
quently genotyped. The genetic relatedness of the P.
aeruginosa isolates in the present study was assessed by
pulsed-field electrophoresis (PFGE), essentially follow-
ing a modification of the method of Durmaz et al. [29].
Genomic DNA was prepared after centrifugation of 1 ml
from a 1.5 McFarland solution obtained from fresh cul-
tures grown on blood agar plates. Pellets were resuspended
in 120 μL of suspension buffer (CSB; 100 mM Tris–HCl
[pH 8.0], 10 mM EDTA) and mixed with an equal volume
of molten (55°C) 2% InCert® agarose (Lonza) prepared in
CSB with 1% sodium dodecyl sulphate (SDS). The DNA
was digested with30 U of SpeI restriction enzyme (New
England Biolabs) and incubated at 37°C for 17 hours. The
digested DNA was electrophoresed in a CHEF-DR III
system (Bio-Rad) with the following running parame-
ters: 6 V/cm at 14°C with pulse times ranging from 5 to
25 seconds for 20 hours. Gels were stained with SYBR®
Safe (Invitrogen) and documented in a ImageQuant™
LAS 4000 (GE Healthcare). Gel images were analyzed using
InfoQuest™ FP software version 4.5 (Bio-Rad, Laboratories).
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with an unweighted pair-group method that uses arithmetic
average (UPGMA) clustering, with a tolerance setting of
1% and optimization of 0.5%. Isolates were defined as the
same PFGE clonal type if the Dice coefficient was ≥90%.
Statistical analysis
The SPSS statistical package version 17.0 (SPSS; Chicago,
Illinois) was used for the statistical analysis. Results for
categorical variables were expressed as absolute and rela-
tive frequencies, and continuous variables were expressed
as means and standard deviations (SD). PA and non-PA
groups were compared for the assessment of factors asso-
ciated with P. aeruginosa isolation, using the chi-square
test with continuity correction for categorical variables.
Quantitative variables were analyzed using Student’s
t-test or the corresponding non-parametrical tests when
required.
Multivariate analysis using stepwise logistic regression
was performed with PA isolation as dependent variable.Table 1 Baseline and clinical characteristics of 118 severe CO
with and without P. aeruginosa isolation
Whole group
Subjects, (%) 118
Follow-up (days), m (SD) 1003 ± 306
Age (years), m (SD) 69.5 ± 8.2
Current smoking, (%) 13 (11)
Pack-year, m (SD) 63.3 ± 31,9
Alcohol abuse >80 g/l, n (%) 3 (2.5)
Influenza vaccination, n (%) 105 (89)
Pneumococcus vaccination n (%) 57 (48.3)
Body mass index (Kgr/m2) 27.5 ± 4.6
FEV1 post-BD, (L), m (SD) 0.97 ± 0.3
FEV1 post-BD, (% predicted), m (SD) 34 ± 11
GOLD stage IV, n (%) 71 (60)
BODE score, m (SD) 5.1 ± 1,6
Home oxygen therapy, n (%) 50 (42.4)
Charlson, m (SD) 4.13 ± 1.5
Bronchiectasis score, m (SD) 2.1 ± 2,6
ECOPD during follow-up, m (SD) 3.19 ± 2.9
ECOPD/year, m (SD) 2.19 ± 2
Antibiotic prescriptions* 8.9 ± 7.5
Antibiotic prescriptions/year 3.3 ± 2.5
Corticosteroid courses* 6.3 ± 5.8
Corticosteroid courses/year 2.30 ± 1.8
Days of hospital stay* 29.4 ± 37.9
Mortality, n (%) 17 (14.4)
Data are presented as means ± SD or n (%), unless otherwise stated. PA group = P. a
post-BD = post bronchodilator. *prior year included.Variables showing a univariate association (p < 0.10) were
included in the model as covariates. Multicollinearity was
evaluated by means of Variance Inflation Factor (VIF);
considering that values below 2.5 in each covariate ruled
out collineality in the model. Results were expressed as
crude and adjusted odds ratios (OR) with 95% confidence
intervals (95% CI). All statistical tests were two-sided, with
a p value of 0.05 or less reported as statistically significant.
Results
Population sample
One hundred eighteen severe COPD patients with a mean
(SD) follow-up of 1003 (306) days were enrolled over the
study period. The study population was predominantly
male, with a mean (SD) age of 69 (8) years, and classified
as GOLD IV in over half of the cases. Clinical characteris-
tics of participating patients at baseline are shown in
Table 1.
A total of 466 sputum samples were obtained at base-
line and during the follow-up, both during exacerbationsPD patients attended for COPD exacerbation (ECOPD),
PA-group Non PA-group P value
41 (34.7) 77 (65,3) …
1036.9 ± 347.5 984.9 ± 282.3 0.41
70.3 ± 7.7 69 ± 8.5 0.42
2 (4.9) 11 (14.3) 0.21
69.4 ± 36.3 60 ± 28.9 0.15
1 (2.4) 2 (2.6) 1
38 (92.7) 67 (87) 0.53
23 (56.1) 34 (44.2) 0.21
26.5 ± 4 28.1 ± 4.9 0.17
0.91 ± 0.28 1.0 ± 0.31 0.13
34 ± 13 34.3 ± 10 0.82
27 (66) 44 (57) 0.35
5.3 ± 1,5 5 ± 1.6 0.38
21 (51.2) 29 (37.7) 0.15
4.29 ± 1.5 4.04 ± 1.5 0.39
3 ± 3.5 1.6 ± 1.8 0.02
4.4 ± 4 2.5 ± 2 0.008
3 ± 2.7 1.7 ± 1.4 0.006
12.5 ± 9.2 7.01 ± 5.7 <0.001
4.7 ± 2.9 2.6 ± 1.8 <0.001
8 ± 6.3 5.5 ± 5.4 0.02
2.9 ± 2 1.9 ± 1.6 0.004
43.8 ± 43.9 21.3 ± 31.9 0.005
11 (27) 6 (8) 0.005
eruginosa group; Non PA group = Non P. aeruginosa group; ns = not significant;
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twenty PPMs were isolated from 263 sputum samples
and in 92 sputum samples no PPM was recovered. The
most frequently isolated bacteria were H. influenzae (94
recoveries, 29.3%) P. aeruginosa (92, 28.7%) S. pneumoniae
(51, 15.9%) and M. catarrhalis (46, 14.3%).Prevalence and risk factors for P. aeruginosa isolation
P. aeruginosa was recovered once or more from sputum
samples in 41 of 118 patients (34.7%) who were included
in the PA group. In five of them, isolates were reported
during the year before inclusion with posterior negative
samples for this PPM during the follow-up period; twenty-
two had isolates growing P. aeruginosa before and during
study period, and in the remaining 14 patients, this PPM
was recovered only during follow-up.
Group comparison showed no significant differences
in age, smoking history, FEV1, body mass index, BODE
score, comorbidities, influenza and pneumococcus vaccin-
ation and long-term oxygen therapy use. Patients in the
PA group had significantly more COPD exacerbations,
higher antibiotic and corticosteroid prescription rates, and
longer hospital stays than the non-PA group (Table 1).
Bronchiectasis were found in 56 patients (47%), with a
mean score of 4.2 (2.5) when present. In 29 patients (51.8%)
bronchiectasis were localized only in lower lobes, and in 12
participants (25.4%) were identified in more than four lobes.
Bronchiectasis scores were significantly higher in the PA
group than in the non-PA group (3 vs 1.6, p = 0.02). Mor-
tality was also significantly higher in the PA group than in
the non-PA group (27% vs 8%, p = 0.005) (Table 1).
For the identification of risk factors for P.aeruginosa
isolation in severe COPD, bronchiectasis were categorized
in three groups according to their extent: 1) No bronchiec-
tasis; 2) bronchiectasis scored 2–5; and 3) bronchiectasis
scored over 5, using the first group as reference category.
Forty-five patients (38%) had scores between 2 and 5, and
11 patients (9%) had more extensive bronchiectasis with
scores higher than 5. Multivariate analysis showed that the
extent of bronchiectasis (OR 9.8, 95% CI: 1.7 to 54.8) and
the number of courses of antibiotic therapy (OR 1.7, 95%
CI: 1.1 to 2.5) were independently associated with an
increased risk of P. aeruginosa isolation in bronchial
secretions (Table 2).Table 2 Results of multivariate analysis of factors
associated with P. aeruginosa isolation
Factor OR 95% CI P value
Bronchiectasis score (>5) 9.8 1.7 - 54.8 0.009
Antibiotic prescriptions/year 1.7 1.1 – 2.5 0.008
Days of hospital stay 1 0.9 - 1 0.3
Corticosteroid courses/year 0.7 0.5 – 1.2 0.2P. aeruginosa colonization and bronchiectasis
Five of 41 patients (12.2%) fulfilled criteria of chronic
colonization by P. aeruginosa without a relationship be-
tween this clinical situation and the extent of bronchiec-
tasis. Three out of five chronically colonized patients (60%)
did not show bronchiectasis on the CT scan; nor did 15
out of 23 patients who had single isolates of P. aeruginosa
(65%) (p = 0.75). The observation of a mucoid morphotype,
however, was significantly associated with a bronchiectasis
score over 5 (p = 0.004), and found in four out of five
patients with this morphotype.
Characterization of P. aeruginosa isolates
Ninety-two positive cultures of P. aeruginosa were recov-
ered from 41 patients, with 78 isolates valid for genotyping,
corresponding to 31 patients. Thirty-six clones were identi-
fied from these 78 isolates, specific for each patient, except
in the case of one clone shared by two patients. Figure 1
shows the overall scheme of the PA group with P. aerugi-
nosa genotyped, and Figure 2 shows the dendogram of
PFGE patterns for the 78 genotyped P. aeruginosa isolates.
Thirteen of 31 patients (41.9%) showed a single P.
aeruginosa isolate with a single clone. Among the
remaining 18 patients with repeated isolates of P. aerugi-
nosa, 12 patients showed the same clone during follow-up,
five of them fulfilling the criteria for chronic colonization.
The assessment of mucoid morphotype in the genotyped
samples demonstrated this morphotype in 11 isolates from
five different patients (numbers 1, 25, 28, 30, and 36; in
Tables 3 and 4) with three clones (P16, P26 and P4) adopt-
ing different morphotypes over time (Tables 3 and 4).
Thirty-seven isolates of P. aeruginosa analyzed were
susceptible to all tested antibiotics (47.4%), 20 were re-
sistant to one or two antibiotic groups (25.6%), while the
remaining 21 were multidrug resistant (26.9%). The anti-
biotic resistance profile of the 78 genotyped P. aeruginosa
isolates is shown in Table 5. Multidrug resistant isolates
were retrieved in five patients (numbers 1, 13, 19, 25 and
29; in Tables 3 and 4), three of them chronically colonized.
These three patients harbored 19 of the 21 multidrug
resistant isolates observed (90%). The clones of all these
patients showed fluctuations in antimicrobial suscepti-
bility over time.
Discussion
Our study showed a high prevalence of P. aeruginosa
isolation in a cohort of severe COPD patients. The extent
of bronchiectasis and recurrent use of antibiotic therapy
were the main risk factors for the recovery of this PPM
from bronchial secretions. Most patients in the PA group
had single isolates of P. aeruginosa, but up to 12% of
patients met criteria for chronic colonization by this PPM,
though this clinical situation was not related to the pres-




78 strains genotyped (PFGE)
10 patients non-genotyped:
(Only one positive culture
for P. aeruginosa) 
13 patients
A single isolate of P. aeruginosa
18 patients
>1 isolate of P. aeruginosa
7 patients













Figure 1 Flow chart illustrating the distribution of PA-group patients with P. aeruginosa isolates genotyped. The indeterminate group
corresponds to patients with three isolates, but only one isolate genotyped.
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in patients with cystic fibrosis.
Prevalence and risk factors for P. aeruginosa isolation
We recovered P. aeruginosa from sputum in nearly 40%
of the severe COPD patients in our series, half of whom
presented bronchiectasis. These figures were similar to
those reported in previous studies in patients with ad-
vanced disease, as shown by Murphy et al. [30] and Renom
et al. [9], who reported P. aeruginosa isolation in over one
third of the sputum samples obtained from COPD patients.
A strong relationship between the extent of bronchiec-
tasis and P. aeruginosa recovery was observed in our
study. Bronchiectasis have been often reported in severe
COPD [10,21,31] but the association between bronchiec-
tasis and P. aeruginosa isolation have been only margin-
ally addressed in previous studies. García-Vidal et al. [8]
analyzed 188 patients with moderate to severe COPD
admitted to hospital for a COPD exacerbation and studied
by HRCT identifying bronchiectasis in 52% of them, with-
out finding significant relationships between bronchiec-
tasis and P. aeruginosa isolation. In a similar population of
201 COPD patients Martínez-García et al. [22] observed
that the isolation of P. aeruginosa was significantly more
frequent in patients with bronchiectasis (13% versus 4.7%).
Our study demonstrated that in COPD patients withadvanced disease the relationship between bronchiectasis
and the recovery of P. aeruginosa is clearly defined and as-
sociated with the extent of the bronchial abnormality.
Additionally, among the other risk factors evaluated for
P. aeruginosa isolation in our study, only the number of
previous antibiotic treatments was independently asso-
ciated with the recovery of this PPM in our study, after
accounting for covariates in the multivariate analysis.
This finding is in agreement with previous studies that
have found a relationship between antibiotic treatments
and the subsequent isolation of P. aeruginosa in sputum
samples [7,8]. The lack of a relationship in the multivariate
analysis between previous hospital admissions and P.
aeruginosa recovery in our study may be attributed to
the differences in study design, because the present study
focus on patients regularly attending an outpatient day
care facility, or to the higher weight of recurrent antibiotic
treatments as a predictor. Although the present study was
not designed to evaluate mortality, we observed a higher
death rate during the follow-up in the PA group, in agree-
ment with other authors [9,32].
Characterization of P.aeruginosa isolates in chronic
colonization
Near 50% of COPD patients (PA-group) had repeated iso-
lates of P. aeruginosa, accomplishing criteria of chronic
Figure 2 Dendogram of PFGE patterns for 78 P. aeruginosa isolates. A genetic similarity index scale is shown above the dendrogram. The
line in the dendrogram denotes the homology threshold of 90% used for defining groups of genetic similarity.
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Table 3 Characteristics of P. aeruginosa isolates genotyped in patients who met criteria for chronic bronchial
colonization by P. aeruginosa
Patient isolates PFGE Genotype ECOPD Isolation date Morphotype
1e P16 No 24/Mar/06 Pseudomonas aeruginosa
1f P32 No 24/Mar/06 Pseudomonas aeruginosa
1a P16 Yes 10/Jan/07 Pseudomonas aeruginosa
1b P16 No 16/Feb/07 Pseudomonas aeruginosa
1g P16 Yes 21/Mar/07 Pseudomonas aeruginosa
1i P16 Yes 21/Mar/07 Pseudomonas aeruginosa mucoid
1c P16 Yes 23/Apr/07 Pseudomonas aeruginosa mucoid
1d P16 Yes 31/May/07 Pseudomonas aeruginosa
25a P26a1 Yes 18/Aug/05 Pseudomonas aeruginosa mucoid
25b P26a1 No 3/Nov/05 Pseudomonas aeruginosa mucoid
25c P26a1 Yes 5/Dec/05 Pseudomonas aeruginosa
25d P26a1 No 9/Jan/06 Pseudomonas aeruginosa mucoid
25e P26a2 No 17/Mar/06 Pseudomonas aeruginosa mucoid
25f P26a1 Yes 11/Jan/07 Pseudomonas aeruginosa mucoid
25g P26b Yes 23/Apr/07 Pseudomonas aeruginosa mucoid
26a P27 Yes 10/Oct/07 Pseudomonas aeruginosa
26b P27 Yes 12/Nov/07 Pseudomonas aeruginosa
26c P27 No 14/Dec/07 Pseudomonas aeruginosa
29a P30a2 Yes 2/Mar/05 Pseudomonas aeruginosa
29b P30a2 No 17/Jun/05 Pseudomonas aeruginosa
29c P30a2 Yes 9/Nov/05 Pseudomonas aeruginosa
29k P30a1 Yes 12/Dec/05 Pseudomonas aeruginosa
29l P30a2 Yes 12/Dec/05 Pseudomonas aeruginosa
29d P30a1 No 23/Jan/06 Pseudomonas aeruginosa
29e P30b No 3/Jul/06 Pseudomonas aeruginosa
29f P30a1 No 18/Sep/06 Pseudomonas aeruginosa
29g P30a2 No 7/Nov/06 Pseudomonas aeruginosa
29h P30a2 No 27/Dec/06 Pseudomonas aeruginosa
29i P30b No 12/Sep/07 Pseudomonas aeruginosa
29j P30b No 17/Dec/07 Pseudomonas aeruginosa
31a P06b Yes 9/Oct/06 Pseudomonas aeruginosa
31b P06b No 21/Nov/06 Pseudomonas aeruginosa
31c P06a Yes 22/Mar/07 Pseudomonas aeruginosa
31d P06a No 27/Apr/07 Pseudomonas aeruginosa
31e P06a Yes 4/Sep/07 Pseudomonas aeruginosa
31f P06b No 17/Oct/07 Pseudomonas aeruginosa
Patients are identified by numbers and different isolates by letters. The PFGE clones are identified by numbers and the superscript indicates same clones with a
Dice coefficient between 90-99%.
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Martinez- García et al. [31] found chronic colonization by
P. aeruginosa in 11/201 moderate-to-severe COPD pa-
tients. The molecular characterization of P. aeruginosa
isolates in our COPD cohort demonstrated the persistenceof the same clone in two thirds of them and in all chronic-
ally colonized patients.
Few studies to date have evaluated chronic colonization
by P. aeruginosa in COPD patients and those that have
been performed have showed conflicting results. Studies
Table 4 Characteristics of P. aeruginosa isolates genotyped in patients without criteria for chronic bronchial
colonization by P. aeruginosa
Patient isolates PFGE Genotype ECOPD Isolation date Morphotype
2a P14 Yes 17/Oct/06 Pseudomonas aeruginosa
2b P33 Yes 15/Feb/08 Pseudomonas aeruginosa
3 P19 Yes 17/Oct/05 Pseudomonas aeruginosa
4 P10 Yes 2/Jun/05 Pseudomonas aeruginosa
5 P04a Yes 22/Mar/06 Pseudomonas aeruginosa
6 P23 Yes 4/Jul/05 Pseudomonas aeruginosa
7a P07 Yes 1/Dec/06 Pseudomonas aeruginosa
7b P07 No 12/Nov/07 Pseudomonas aeruginosa
8a P31 No 8/Sep/05 Pseudomonas aeruginosa
8b P31 No 12/Dec/05 Pseudomonas aeruginosa
9 P12 Yes 14/Dec/07 Pseudomonas aeruginosa
10 P28 Yes 10/Aug/06 Pseudomonas aeruginosa
11 P29 Yes 5/Oct/07 Pseudomonas aeruginosa
12a P13 Yes 7/Apr/05 Pseudomonas aeruginosa
12b P13 No 18/Oct/05 Pseudomonas aeruginosa
13a P34 Yes 30/May/06 Pseudomonas aeruginosa
13b P02 Yes 11/Oct/06 Pseudomonas aeruginosa
14a P18 Yes 28/Jan/06 Pseudomonas aeruginosa
14b P18 Yes 28/Jul/06 Pseudomonas aeruginosa
15 P05 Yes 2/Feb/06 Pseudomonas aeruginosa
16a P15 Yes 23/Nov/05 Pseudomonas aeruginosa
16b P15 Yes 3/Jan/06 Pseudomonas aeruginosa
17a P20 Yes 3/Nov/05 Pseudomonas aeruginosa
17b P20 Yes 22/Dec/05 Pseudomonas aeruginosa
17c P20 Yes 8/Jun/06 Pseudomonas aeruginosa
19a P25 Yes 19/Dec/05 Pseudomonas aeruginosa
19b P35 No 12/Jun/06 Pseudomonas aeruginosa
19c P17 Yes 3/Mar/08 Pseudomonas aeruginosa
20 P03 Yes 28/Nov/06 Pseudomonas aeruginosa
21 P01 Yes 4/Feb/08 Pseudomonas aeruginosa
23 P24 Yes 6/Mar/06 Pseudomonas aeruginosa
24 P09 Yes 30/Jun/06 Pseudomonas aeruginosa
27a P08 Yes 20/Mar/06 Pseudomonas aeruginosa
27b P08 No 12/Apr/06 Pseudomonas aeruginosa
27c P08 No 25/Jul/07 Pseudomonas aeruginosa
28 P11 Yes 11/Oct/07 Pseudomonas aeruginosa mucoid
30a P04a Yes 10/Jan/07 Pseudomonas aeruginosa
30b P04b No 21/Feb/07 Pseudomonas aeruginosa mucoid
30c P22 No 19/Dec/07 Pseudomonas aeruginosa
30d P22 Yes 8/Feb/08 Pseudomonas aeruginosa
36 P36 Yes 23/May/05 Pseudomonas aeruginosa mucoid
32 P21 Yes 10/Nov/06 Pseudomonas aeruginosa
Patients are identified by numbers and different isolates by letters. The PFGE clones are identified by numbers and the superscript indicates same clones with a
Dice coefficient between 90-99%.
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Table 5 Antibiotic resistance profile of 78 P. aeruginosa
isolates


















Polymyxins Colistin 76 (97.4)
Monobactams Aztreonam 59 (75.6)
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respiratory samples showed a chronic infection pattern
similar to cystic fibrosis [14,15] in a limited number of
COPD patients. Conversely, in a 10-year follow-up study
which included 126 COPD patients, Murphy et al. [30]
observed two distinct patterns of carriage of P. aeruginosa:
a more frequent pattern of short-term carriage followed
by clearance of the strain in up to half of episodes, and a
persistence pattern of the same strain in a quarter of the
episodes. Rakhimova et al. [13] genotyped P. aeruginosa
isolates from this cohort and compared them with strains
recovered from patients with cystic fibrosis showing
chronic P. aeruginosa infection (n = 128), concluding that
sporadic or intermittent infection with P. aeruginosa was
the most common finding in bronchial secretions from
COPD patients, who presented a frequent clone turnover,
a pattern that differs from the chronic carriage of P. aeru-
ginosa clones found in cystic fibrosis. Our results confirm
that although the most frequent pattern in severe COPD
is a self-limited isolation of P. aeruginosa, over ten per
cent of severe patients show chronic colonization by P.
aeruginosa, with clonal persistence pattern in close simi-
larity with cystic fibrosis. A relationship with the extent of
bronchiectasis was not observed in our study in this sub-
set of patients, however. Determinants other than bron-
chiectasis that were not evaluated in our study, such as
virulence factors or biofilm production, could explain the
ability of P. aeruginosa to colonize these patients [14].More than half of the isolates recovered from chronically
colonized patients who harbor the same clone showed
multidrug resistance and presented fluctuations in their
antimicrobial susceptibility over the time. This variability
in the antibiogram of P. aeruginosa has been reported
previously [33] in cystic fibrosis, suggesting a polyclonal
population that may not be well represented in sputum
cultures. Similarly, some P. aeruginosa clones in our study
adopted both mucoid and non-mucoid phenotypes during
the follow-up, a finding that has also been reported in cys-
tic fibrosis [34]. Finally, although the mucoid morphotype
is considered a marker of colonization [35], in our study it
was mainly related to high score of bronchiectasis.Limitations
Patients from a selected COPD population participated
in this study and our results can not be extrapolated to
the COPD population as a whole. Only patients with severe
COPD and frequent exacerbations who were managed on
an outpatient basis at a day care facility were enrolled: re-
sults in these patients may not be applicable to patients
who require recurrent admissions when exacerbation symp-
toms appear or has less severe disease. Additionally, micro-
biological analyses were performed only in spontaneous
sputum samples, and no information on bronchial flora
was obtained from patients or from episodes without spu-
tum production. These limitations, however, do not reduce
the significance of the results obtained, considering that
spontaneous sputum production is the most common situ-
ation for these patients during exacerbations.Conclusions
In summary, our study suggests a high prevalence of P.
aeruginosa isolations in severe COPD patients. The extent
of bronchiectasis and the number of antibiotic treatment
regimens received were the main independent risk factors
for the recovery of this PPM. Moreover, over one tenth
of COPD patients met criteria for chronic colonization
by P. aeruginosa and showed clonal persistence of this
PPM regardless of the extent of bronchiectasis.
These findings have clinical implications for the man-
agement of severe COPD patients with frequent exacer-
bations, who may need the performance of CT scans
and repeated sputum cultures for the identification of
bronchiectasis and bronchial colonization by this PPM.
P. aeruginosa must be considered a common causative
agent in these patients, especially in those with a high ex-
tent in their bronchiectasis and receiving frequent antibiotic
treatment. According to our data, a close follow-up may be
recommended when P. aeruginosa is isolated in sputum
cultures, for an early identification of chronic colonization,
a situation which will require an approach similar to that
applied in cystic fibrosis.
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